SFSIG
VIVO

San Francisco Sentry Investment Group’s Meridian Bioscience Inc VIVO Stock Holding History

San Francisco Sentry Investment Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,580
Closed -$37K – 666
2013
Q3 		$37K Buy
1,580
+285
+22% +$6.66K 0.01% 349
2013
Q2 		$28K Buy
+1,295
New +$27.9K 0.01% 379

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

San Francisco Sentry Investment Group's VIVO Position: Q4 2013 in Review

San Francisco Sentry Investment Group sold out of Meridian Bioscience Inc (VIVO) in Q4 2013, closing a stake of 1,580 shares — an estimated $37K sold.

San Francisco Sentry Investment Group first reported a position in VIVO in Q2 2013 and held it in 2 quarters. The position peaked at $37K in Q3 2013. 170 funds tracked by Wall St. Rank hold VIVO as of Q4 2013.

  • San Francisco Sentry Investment Group reported no remaining Meridian Bioscience Inc position as of Q4 2013 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 1,580 Meridian Bioscience Inc shares in Q4 2013, an estimated $37K.
  • San Francisco Sentry Investment Group first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 2 quarters.
  • San Francisco Sentry Investment Group's Meridian Bioscience Inc position peaked at $37K in Q3 2013.
  • 170 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2013.

Based on San Francisco Sentry Investment Group's 13F filing for Q4 2013, filed 22 Jan 2014.